Description:
Asunaprevir is a potent hepatitis C virus (HCV) non-structural protein protease inhibitor currently in Phase III clinical trials for the treatment of HCV infection.
- Molecular Weight: 748.29
- Molecular Formula: C35H46ClN5O9S
Purity: >98%
Canonical SMILES:
CC(C)(C)C(C(=O)N1CC(CC1C(=O)NC2(CC2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
InChI:
InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1
InChIKey: XRWSZZJLZRKHHD-WVWIJVSJSA-N
- Melting Point: 145-155 °C
- Solubility: In Vitro: DMSO: ≥ 42.9 mg/mL (57.33 mM)
- Appearance: Solid powder
- Application: Protease Inhibitors
- Storage: Powder: -20°C 3 years4°C 2 yearsIn solvent: -80°C 6 months-20°C 1 months
Synonyms:
BMS-650032; BMS 650032; BMS650032; Asunaprevir. brand name: Sunvepra
More details are to be found on supplier website
